Publications by authors named "Linus Spatz"

Claim this Profile
O
Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.
Alicia Fayad, Iliana Principi, Alejandro Balestracci, Laura Alconcher, Paula Coccia, Linus Spatz

Pediatr Nephrol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome.
Marta Rivas, Mariana Pichel, Vanesa Zylberman, Mariana Colonna, Marina Valerio, Linus Spatz

Toxins (Basel)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab') fragments in healthy volunteers.
Yanina Hiriart, Paula Scibona, Augusto Ferraris, Waldo H Belloso, Valeria Beruto, Linus Spatz

Br J Clin Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina.
Marta Rivas, Mariana Pichel, Mariana Colonna, Adrián López Casanello, Laura F Alconcher, Linus Spatz

Rev Argent Microbiol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.
Diego H Farizano Salazar, Fernando Achinelli, Mariana Colonna, Lucía Pérez, Analía A Giménez, Linus Spatz

PLoS One· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RBD-specific polyclonal F(ab´) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.
Gustavo Lopardo, Waldo H Belloso, Esteban Nannini, Mariana Colonna, Santiago Sanguineti, Linus Spatz

EClinicalMedicine· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.
Vanesa Zylberman, Santiago Sanguineti, Andrea V Pontoriero, Sandra V Higa, María L Cerutti, Linus Spatz

Medicina (B Aires)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of wild populations of Biomphalaria spp. from neotropical South America to Schistosoma mansoni and interference of Zygocotyle lunata.
Linus Spatz, Stella Maris Gonzalez Cappa, Margarita Ostrowski de Núñez

J Parasitol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the first and second internal transcribed spacer sequences of the ribosomal DNA in Biomphalaria tenagophila complex (Mollusca: Planorbidae).
Teofânia H D A Vidigal, Linus Spatz, Jessica C Kissinger, Rodrigo A F Redondo, Edina C R Pires

Mem Inst Oswaldo Cruz· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis